2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 458

The TAM Receptors Axl and Mer Play a Protective Role in a Temporal and Spatial Manner in Inflammatory Arthritis
Abstract Number: 668

The TNFAIP3 F127C Coding Variation in Sjogren’s Syndrome: Results from a Greek Cohort
Abstract Number: 1909

The Transcription Factor Fra2 Is Playing a Key Role in Treg Development and Autoimmunity
Abstract Number: 662

The Unusual Cross-Reactivity of Anti Muscarinic Receptor 3 Monclonal Antibodies Derived from Salivary Glands of Sjögren’s Syndrome Patients to Ro Peptides
Abstract Number: 1186

The Use of Clinical Mucosal Manifestations to Differentiate Patients with Lupus and Dermatomyositis: Transversal, Retrospective and Analytical Study of 116 Patients
Abstract Number: 781

The Use of Rituximab in Newly Diagnosed Systemic Lupus Erythematosus Patients: Long Term Steroid Saving Capacity and Clinical Effectiveness
Abstract Number: 141

The Usefulness of SMI Technology on Ultrasound for the Evaluation of Active Synovitis in Patients with Rheumatoid Arthritis
Abstract Number: 1290

The Usefulness of Volumetric Parameters of FDG PET/CT for Reflecting Disease Activity in Polymyositis/Dermatomyositis Patients
Abstract Number: 889

The Utility of Patient-Reported Outcomes in Predicting Disease Activity in Patients with Takayasu’s Arteritis
Abstract Number: 10

The Utility of Screening for Infectious Diseases in Recipients of Anti-TNF-α Therapy
Abstract Number: 3181

The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis
Abstract Number: 320

The Value of Adjusting for Physical Activity When Measuring Osteoarthritis-Related Pain
Abstract Number: 2425

The Vasculopathy of Juvenile Dermatomyositis (JDM); Evidence of Persistent Endothelial Injury, Hypercoagulability, Subclinical Inflammation and Increased Arterial Stiffness
Abstract Number: 1139

The Virtual Rheumatology Clinic: Virtual Patients for Resident Education in Rheumatology
Abstract Number: 1447

Therapeutic Blockade of Interleukin-6 Trans-Signalling Restores Vascular Function in Murine Collagen Induced Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].